13 MAY 2014 - IPHARMA Becomes a Leader in Russian Clinical Trials
IPHARMA, a clinical division of the ChemRar/ChemDiv group, is the top contract research organization in terms of the number of local clinical trials of Russian innovative medicines conducted in 2013. This information is published in the latest issue of the Association of Clinical Trials Organizations (ACTO) Newsletter from April 14, 2014. IPHARMA specializes in organizing and conducting clinical trials.
In its 2013 analytical report, ACTO amassed data among companies conducting clinical trials of innovative medicines and bioequivalence studies on generic medicines. Projects managed by IPHARMA are primarily clinical trials of new drugs in the fields of oncology, endocrinology, viral diseases, neurology, and other therapeutic areas. One of IPHARMA’s key strengths is managing early-phase trials (Phase 1 and 2), which are key stages to evaluate prospective drugs for further development.
IPHARMA’s efforts are aimed at the development of new medicines in partnership with major international pharmaceutical companies, such as F. Hoffmann-La Roche, Johnson & Johnson, Abbott, as well as a new generation of smaller companies and startups, such as Dompé, SatRx, Viriom, NewVac, Avineuro.
Per Chief Operating Officer Natalia Vostokova, IPHARMA is focused on the needs of both Russian and global customers. “We undertake complex projects with great focus to achieve successful results. As a successor to the traditions of ChemRar, we endeavor to invest our knowledge and experience into the development of Russian and international innovative medicines”, she stated.
Nikolay Savchuk, a member of the Board of the ChemRar High Tech Center, said, “IPHARMA skillfully cooperates with its global partners in Europe, Asia, Africa, Australia, and North and South America to conduct extremely high quality, time and cost effective studies.
Fundamental to the company’s success is its combination of knowledge of the regulatory environment, development of study protocols, access to patients, and compliance with international quality standards for clinical trials”.